Quince Therapeutics, Inc. — Form 10-Q

On May 14, 2026, Orphai Therapeutics (Customer) entered a License and Supply Agreement with Plastiape S.p.A. (Supplier, Italy) for inhalation devices. Key terms: (1) Supplier manufactures devices; Customer integrates into finished drug-device combination products. (2) Exclusivity granted for specified molecules/APIs during stated term, contingent on minimum purchase quantities; failure to meet minimums allows cure via payment of redacted Exclusivity Fee or unspecified alternative. (3) Supplier retains all IP; Customer gets limited right of reference for regulatory filings only. (4) Price, payment terms, forecasts, and operational details redacted. (5) Term: initial period [redacted] then indefinite; Supplier can terminate post-initial term on [redacted] notice; Customer can terminate anytime on [redacted] notice. (6) Liability capped at [redacted]; exclusivity disputes subject to injunctive relief. Schedules 1–4 (specifications, regulatory status, exclusivity details, pricing, commercial terms) heavily redacted.